SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.52), $0.09 better than the analyst estimate of ($1.61).

Financial Guidance: Sage expects that its existing cash, cash equivalents and marketable securities will fund its anticipated level of operations, based on its current operating plans, into the second quarter of 2018.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.